We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Humanigen’s Lenzilumab for COVID-19 Draws FDA Complete Response Letter
Humanigen’s Lenzilumab for COVID-19 Draws FDA Complete Response Letter
The FDA has declined to grant Humanigen an emergency use authorization (EUA) for its antibody lenzilumab for treatment of hospitalized COVID-19 patients.